1 | at the university of | | | | | | | 3 | 0.21% |
2 | phase iia study of | | | | | | | 3 | 0.21% |
3 | a fellow of the | | | | | | | 3 | 0.21% |
4 | of novel 5meodmt formulation | | | | | | | 2 | 0.14% |
5 | formulation bpl003 for treatment | | | | | | | 2 | 0.14% |
6 | study of novel 5meodmt | | | | | | | 2 | 0.14% |
7 | data from phase iia | | | | | | | 2 | 0.14% |
8 | initial data from phase | | | | | | | 2 | 0.14% |
9 | positive initial data from | | | | | | | 2 | 0.14% |
10 | 2024 beckley psytech announces | | | | | | | 2 | 0.14% |
11 | beckley canopy therapeutics a | | | | | | | 2 | 0.14% |
12 | novel 5meodmt formulation bpl003 | | | | | | | 2 | 0.14% |
13 | beckley psytech’s phase i | | | | | | | 2 | 0.14% |
14 | treatment resistant depression in | | | | | | | 2 | 0.14% |
15 | the university of pittsburgh | | | | | | | 2 | 0.14% |
16 | the university of maryland | | | | | | | 2 | 0.14% |
17 | of maryland school of | | | | | | | 2 | 0.14% |
18 | maryland school of medicine | | | | | | | 2 | 0.14% |
19 | dose of bpl003 was | | | | | | | 2 | 0.14% |
20 | and pharmacodynamics of bpl003 | | | | | | | 2 | 0.14% |
21 | for treatment resistant depression | | | | | | | 2 | 0.14% |
22 | bpl003 for treatment resistant | | | | | | | 2 | 0.14% |
23 | university of maryland school | | | | | | | 2 | 0.14% |
24 | the form please try | | | | | | | 1 | 0.07% |
25 | tim is an experienced | | | | | | | 1 | 0.07% |
26 | having formerly served as | | | | | | | 1 | 0.07% |
27 | formerly served as head | | | | | | | 1 | 0.07% |
28 | served as head of | | | | | | | 1 | 0.07% |
29 | as head of clinical | | | | | | | 1 | 0.07% |
30 | head of clinical development | | | | | | | 1 | 0.07% |
31 | of clinical development for | | | | | | | 1 | 0.07% |
32 | beckley canopy therapeutics and | | | | | | | 1 | 0.07% |
33 | canopy therapeutics and as | | | | | | | 1 | 0.07% |
34 | therapeutics and as an | | | | | | | 1 | 0.07% |
35 | and as an advisor | | | | | | | 1 | 0.07% |
36 | as an advisor to | | | | | | | 1 | 0.07% |
37 | an advisor to the | | | | | | | 1 | 0.07% |
38 | advisor to the beckley | | | | | | | 1 | 0.07% |
39 | foundation tim is an | | | | | | | 1 | 0.07% |
40 | is an experienced cannabis | | | | | | | 1 | 0.07% |